Illumina jumps as investors lean into 2026 outlook and SomaLogic integration
Illumina shares rose after investors revisited the company’s February 5, 2026 results and 2026 outlook, which called for $4.5–$4.6B revenue and $5.05–$5.20 non-GAAP EPS. Optimism has also been supported by the recently closed SomaLogic acquisition, which management expects to add 1.5%–2.0% to 2026 revenue growth.
1. What’s moving the stock
Illumina (ILMN) is higher today as traders and longer-term investors refocus on the company’s 2026 financial framework laid out with its fourth-quarter and full-year 2025 report, alongside the strategic rationale of its proteomics expansion. Illumina guided 2026 total revenue to $4.5 billion to $4.6 billion and non-GAAP diluted EPS to $5.05 to $5.20, explicitly including benefits and dilution tied to SomaLogic. (illumina.com)
2. Why the 2026 narrative matters now
The core debate around ILMN has centered on whether the business can sustain a return to growth while navigating uneven research spending and instrument cycles. Illumina’s February outlook pointed to 4%–6% reported revenue growth for 2026, with ex-China organic growth of 2%–4%, and reiterated that clinical market momentum is building. That combination has been a key reference point for dip-buyers and momentum traders when the stock shows strength. (illumina.com)
3. SomaLogic as the incremental catalyst
Illumina closed its acquisition of SomaLogic on January 30, 2026, adding a scaled proteomics platform to Illumina’s broader multiomics strategy. In its February guidance, Illumina said the recently closed SomaLogic deal is expected to provide a 1.5%–2.0% benefit to 2026 revenue growth, alongside about 100 basis points of non-GAAP operating margin impact and $0.18 of non-GAAP EPS dilution. (investor.illumina.com)
4. What to watch next
Near-term, investors will focus on signs that clinical demand and multiomics adoption can offset softer research consumables trends, and that SomaLogic integration can translate into cross-selling and workflow expansion without additional margin pressure. Any incremental updates around the pace of proteomics commercialization, large customer wins, or reaffirmation/adjustment of 2026 guidance could quickly become the next driver of single-day moves in ILMN. (illumina.com)